PRESS RELEASE
Unicorn Capital Advisers in Russia has guided Ilmix Group through the process of selling the Group's prescription drug and food supplement portfolio to Acino, a Swiss pharmaceutical company.
Ilmix Group (https://indinol.ru) is a full-cycle pharmaceutical company that operates the entire process from new molecule research and development to in-house production and sale of patent-protected medication. Founded in 2003, it is one of the top leaders in the Russian market's commercial segment; it specialises in selling non-hormonal drugs for men's and women's reproductive health and cancer prevention, with the ultimate goal of developing, producing and promoting innovative medication based on natural compounds.
Acino (www.acino.swiss) is a Zurich-based company that focuses its strategy on specific markets in the Middle East, Africa, Russia, the CIS and Latin America. Its Russian branch, Acino Rus, was founded in 2015 and is now one of the most dynamically growing companies in the targeted segments of the Russian market. The company boasts a diverse portfolio of medication for preventing and treating women's health issues and urologic and proctologic conditions.
Denis Glyadyayev, General Manager, Acino Rus, says: «This agreement opens up new opportunities for Acino's growth in the Russian market. Expanding the portfolio of pharmaceuticals allows us to make a more powerful and comprehensive offer to healthcare representatives and patients. It also strengthens the company's position in international emerging markets as a reliable partner and a leading supplier of high-
quality pharmaceuticals».
Sergei Zhdanov, Chairman, IlmixGroup: «Our company has transformed from a small team of like-minded people who implemented the advanced scientific ideas of the outstanding scientist Mr. Kiselev into a full-cycle pharmaceutical company whose products were highly appreciated by the multinational company Acino. I would like to note the participation of Unicorn team whose professional involvement at every stage and their intention of achieving results allowed to take account of all parties’ interests and close a cross- border transaction, thanks to which our portfolio of truly innovative pharmaceuticals will receive a new impetus for development».
Sergei Moiseyev, Chairman, Unicorn Capital Advisers: «We believe this deal to be a milestone in Russian pharmaceutical sector and are honored to be part of it. The Unicorn experience has ensured top-notch quality of every negotiation aspect, reaffirming our utmost competence in complex deal structuring».
###
Unicorn Capital Advisers offers leading advice on M&A and capital raising, provides management consulting to improve corporate governance.
More information is available at www.unicorncapital.com
Ilmix Group (https://indinol.ru) is a full-cycle pharmaceutical company that operates the entire process from new molecule research and development to in-house production and sale of patent-protected medication. Founded in 2003, it is one of the top leaders in the Russian market's commercial segment; it specialises in selling non-hormonal drugs for men's and women's reproductive health and cancer prevention, with the ultimate goal of developing, producing and promoting innovative medication based on natural compounds.
Acino (www.acino.swiss) is a Zurich-based company that focuses its strategy on specific markets in the Middle East, Africa, Russia, the CIS and Latin America. Its Russian branch, Acino Rus, was founded in 2015 and is now one of the most dynamically growing companies in the targeted segments of the Russian market. The company boasts a diverse portfolio of medication for preventing and treating women's health issues and urologic and proctologic conditions.
Denis Glyadyayev, General Manager, Acino Rus, says: «This agreement opens up new opportunities for Acino's growth in the Russian market. Expanding the portfolio of pharmaceuticals allows us to make a more powerful and comprehensive offer to healthcare representatives and patients. It also strengthens the company's position in international emerging markets as a reliable partner and a leading supplier of high-
quality pharmaceuticals».
Sergei Zhdanov, Chairman, IlmixGroup: «Our company has transformed from a small team of like-minded people who implemented the advanced scientific ideas of the outstanding scientist Mr. Kiselev into a full-cycle pharmaceutical company whose products were highly appreciated by the multinational company Acino. I would like to note the participation of Unicorn team whose professional involvement at every stage and their intention of achieving results allowed to take account of all parties’ interests and close a cross- border transaction, thanks to which our portfolio of truly innovative pharmaceuticals will receive a new impetus for development».
Sergei Moiseyev, Chairman, Unicorn Capital Advisers: «We believe this deal to be a milestone in Russian pharmaceutical sector and are honored to be part of it. The Unicorn experience has ensured top-notch quality of every negotiation aspect, reaffirming our utmost competence in complex deal structuring».
###
Unicorn Capital Advisers offers leading advice on M&A and capital raising, provides management consulting to improve corporate governance.
More information is available at www.unicorncapital.com
March 31, 2021
Unicorn Capital Advisers served as financial advisor to Ilmix Group (Russia) in regard to its prescription drug and food supplement portfolio acquisition by Acino (Switzerland)
Unicorn Capital Advisers contacts:
Sergei Moiseyev, Chairman
Mbl. +7 967 119-90-00
sergei.moiseyev@unicorncapital.ru
Tatiana Nikitina, Director, IR and communications
Mbl. +7 967 119-92-22
tatiana.nikitina@unicorncapital.ru
Sergei Moiseyev, Chairman
Mbl. +7 967 119-90-00
sergei.moiseyev@unicorncapital.ru
Tatiana Nikitina, Director, IR and communications
Mbl. +7 967 119-92-22
tatiana.nikitina@unicorncapital.ru